•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•

Copenhagen, Denmark, April 19, 2026 – Zealand Pharma A/S (“the Company” or “Zealand Pharma”) (Nasdaq: ZEAL) has received information on transactions in Zealand Pharma’s shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons. The Company publishes this information in accordance with applicable disclosure requirements.
Please see the attached file(s).
Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on advancing medicines for obesity and metabolic health. Combining more than 25 years of peptide R&D expertise with a proprietary data platform that leverages advanced data driven and AI/ML approaches, Zealand Pharma aims to lead a new era in obesity and metabolic health. To date, more than 10 Zealand Pharma invented drug candidates have entered clinical development, of which two products have reached the market and three candidates are in late-stage development. The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization. Founded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with a U.S. presence in Boston, Massachusetts.
Eric Rojas (Investors), Vice President, Head of Investor Relations, Zealand Pharma
Email: ero jas@zealandpharma.com
Adam Lange (Investors), Vice President, Investor Relations, Zealand Pharma
Email: alange@zealandpharma.com
Neshat Ahmadi (Investors), Investor Relations Manager, Zealand Pharma
Email: neahmadi@zealandpharma.com
Rachel James-Owens (Media), Vice President, Corporate Communications and Media Relations, Zealand Pharma
Email: RjamesOwens@zealandpharma.com
Andreas Hylleberg Mølleskov (Media), Director, External Communications, Zealand Pharma
Email: AHylleberg@zealandpharma.com
19042026 - PDMR transactions
Premium gym chains are entering a “golden era” that is ending or already in decline, as rising operating costs collide with shifting consumer preferences toward more flexible, community-based ways to exercise. Long-term memberships are shrinking, margins are pressured by higher rents and facility expenses, and competition from smaller, more personalized…